Advanced Bladder Cancer COE

The Role of Risk-Stratified Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer Who Are Undergoing Radical Cystectomy - Arlene O. Siefker-Radtke and Shilpa Gupta

Details
In this conversation, Arlene Siefker-Radtke and Shilpa Gupta join Patrick Hensley to discuss the role of risk-stratified neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer who are undergoing radical cystectomy. Drs. Siefker-Radtke and Gupta explain how systemic chemotherapy can be very challenging for bladder cancer patients due to the long-term side effects it can cause, alo...

Outcomes Between Patients With and Without Prior Intravesical BCG, Who Received Immune Checkpoint Inhibitors for Advanced Urothelial Carcinoma - Rafee Talukder & Petros Grivas

Details
In this conversation with Alicia Morgans, Rafee Talukder and Petros Grivas share data that investigates comparing the outcomes in patients who received prior intravesical BCG, and those patients who progressed and then required immune checkpoint inhibitors, to see if prior BCG therapy had an effect on the response on immune checkpoint inhibitors. Their hypothesis was, that patients who received BC...

The Effect of Durvalumab and Olaparib on Prolong Progression-Free Survival As First-Line Therapy in Platinum-Ineligible Patients With Unresectable Urothelial Carcinoma - The BAYOU Study – Jonathan Ros...

Details
Jonathan Rosenberg joins Alicia Morgans to discuss the results of the BAYOU trial. BAYOU is a randomized phase II study examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma. Biographies: Jonathan E. Rosenberg, MD, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; and the Enno W....

The Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab in the Treatment of Cisplatin-Ineligible Patients in Advanced Urothelial Carcinoma (LEAP-011) – Yohann Loriot

Details
Yohann Loriot joins Sam Chang to discuss the results of the LEAP-011 trial which was designed to compare first-line pembrolizumab and lenvatinib to pembrolizumab monotherapy as first-line treatment of patients with advanced urothelial cancer (aUC) who are cisplatin-ineligible with PD-L1–positive tumors or are ineligible to receive platinum-based chemotherapy. Biographies: Yohann Loriot, PhD, MD, G...

DS8201-a-U105 Trial of Trastuzumab Deruxtecan With Nivolumab in Patients With Urothelial Carcinoma – Matt Galsky

Details
Alicia Morgans and Matthew Galsky discuss a two-part open-label study of trastuzumab deruxtecan with nivolumab in patients with HER2 expressing urothelial carcinoma. Dr. Galsky provides background on the rise of combination therapies of antibody-drug conjugates and immune checkpoint blockades in urothelial cancer. They also discuss the preliminary success of this combination therapy and that we wi...

Clinical Outcomes With Anti-PD(L)1 Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma – Dimitrios Makrakis

Details
Dimitrios Makrakis joins Alicia Morgans and Petros Grivas in a discussion on a BJU International publication titled The Association of prior local therapy and outcomes with PD(L)1 inhibitor in advanced urothelial cancer looking at a data set trying to understand the important potential interaction between exposure to checkpoint inhibitors and local therapy for patients at the time of diagnosis ass...

Practice-Changing and Emerging Treatment Strategies in Metastatic Urothelial Carcinoma - Guru Sonpavde

Details
Guru Sonpavde joins Ashish Kamat sharing takeaways from the 2021 ESMO meeting starting with practice-changing or practice reaffirming studies, followed by other emerging drugs and data. Dr. Sonpavde highlighted the landmark phase 3 EV-301 study that led to the approval of enfortumab vedotin in post-platinum and PD-1 inhibitor-treated patients with metastatic urothelial carcinoma. Among the other s...

Cisplatin-Related Immunomodulation and Efficacy with Atezolizumab + Cisplatin Versus Carboplatin-Based Chemotherapy in Metastatic Urothelial Cancer - Matthew Galsky

Details
In this conversation with Alicia Morgans, Matthew Galsky highlights an exploratory analysis within the IMvigor130 randomized phase III study of patients with metastatic urothelial cancer who were treatment-naive. IMvigor130 was asking two separate questions, should we combine platinum-based chemotherapy with atezolizumab versus giving platinum-based chemotherapy alone, and should we give immune ch...

Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas

Details
Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...

Implications for Genetic Testing in Urothelial Cancer - Guru Sonpavde & Maria Carlo

Details
In this UroToday discussion between Petros Grivas, MD, PhD, Guru Sonpavde, MD, and Maria Carlo, MD, the trio discuss recent publications on germline testing and genetic profiling. The conversation kicks off with a background on Dr. Carlo’s recent work concerning genetic testing for urothelial and bladder cancer patients. The conversation shifts to hear from Dr. Sonpavde about his recent work in lo...
email news signup